Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 150.31 |
| Open | 154.41 |
| Bid | 152.29 x 200 |
| Ask | 152.55 x 100 |
| Day's Range | 151.91 - 155.41 |
| 52 Week Range | 141.98 - 218.88 |
| Volume | |
| Avg. Volume | 838,431 |
| Market Cap | 19.269B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Insider Monkey
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript May 2, 2024 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.52272, expectations were $-0.75. ALNY isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for […]
- Zacks
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
- Simply Wall St.
Alnylam Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
Alnylam Pharmaceuticals ( NASDAQ:ALNY ) First Quarter 2024 Results Key Financial Results Revenue: US$494.3m (up 55...
© 2024 Yahoo. All rights reserved.